Kymera Therapeutics, Inc. (KYMR)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 2.8M | 2.9M | 34.4M | 65.0M |
| Operating Income | (88.7M) | (97.9M) | (84.2M) | (75.6M) |
| Net Income | (82.2M) | (87.0M) | (69.2M) | (61.2M) |
| Diluted EPS | $-0.94 | $-0.97 | $-0.71 | $-0.62 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 46.8M | 78.6M | 47.1M | 39.2M |
| Operating Income | (161.3M) | (165.5M) | (256.7M) | (345.5M) |
| Net Income | (154.8M) | (147.0M) | (223.9M) | (311.4M) |
| Diluted EPS | $-2.87 | $-2.52 | $-2.98 | $-3.69 |